Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2021 10:47 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals annonce l'autorisation par la Commission européenne de l'IMCIVREE® (setmelanotide) ▼ pour le contrôle de la faim et le traitement de l'obésité associés au déficit en POMC, en PCSK1 ET en LEPR

BOSTON, 27 juill. 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique au stade commercial qui s'est engagée à transformer les soins apportés aux...
July 27, 2021 10:47 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals gibt Zulassung der Europäischen Kommission für IMCIVREE® (Setmelanotid)▼ für die Behandlung von Adipositas und zur Kontrolle des Hungergefühls im Zusammenhang mit einem POMC-, PCSK1- und LEPR-Mangel bekannt

BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich dem Ziel verschrieben hat, die...
July 27, 2021 10:47 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals anuncia la autorización de la Comisión Europea de IMCIVREE® (setmelanotida)▼ para el tratamiento de la obesidad y el control del hambre asociados a la deficiencia de POMC, PCSK1 y LEPR

BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), empresa biofarmacéutica en fase comercial comprometida con la transformación del cuidado de las personas que...
July 27, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...
July 23, 2021 08:50 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

BOSTON, July 23, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
July 22, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel

BOSTON and PETACH TIKVA, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of...
May 27, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...
May 21, 2021 08:39 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
May 05, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference

BOSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living...
May 03, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at...